share_log

Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW) Short Interest Update

Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW) Short Interest Update

鳳凰生物科技收購公司(納斯達克:PBAXW)空頭股數更新
kopsource ·  2022/08/28 12:01

Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW – Get Rating) was the target of a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 2,400 shares, a drop of 64.2% from the July 31st total of 6,700 shares. Based on an average daily volume of 13,000 shares, the days-to-cover ratio is currently 0.2 days.

鳳凰生物科技收購公司(納斯達克代碼:PBAXW-GET Rating)是空頭股數8月份大幅下跌的目標。截至8月15日,空頭股數共有2400股,較7月31日的6700股下降了64.2%。以日均成交量13,000股計算,目前天數與回補比率為0.2天。

Phoenix Biotech Acquisition Price Performance

鳳凰生物科技收購價格表現

Shares of NASDAQ PBAXW remained flat at $0.09 during midday trading on Friday. 58,315 shares of the stock were exchanged, compared to its average volume of 27,935. Phoenix Biotech Acquisition has a twelve month low of $0.07 and a twelve month high of $0.58. The stock's fifty day simple moving average is $0.09.

在週五午盤交易中,納斯達克的股價持平於0.09美元。該股共成交58,315股,而其平均成交量為27,935股。菲尼克斯生物科技公司的收購價格為0.07美元的12個月低點和0.58美元的12個月高點。該股的50日簡單移動均線切入位為0.09美元。

Get
到達
Phoenix Biotech Acquisition
收購鳳凰生物科技
alerts:
警報:

Institutional Investors Weigh In On Phoenix Biotech Acquisition

機構投資者參與鳳凰生物科技的收購

A number of institutional investors have recently added to or reduced their stakes in the stock. Clear Street LLC acquired a new stake in Phoenix Biotech Acquisition in the 2nd quarter valued at $33,000. MMCAP International Inc. SPC lifted its holdings in Phoenix Biotech Acquisition by 200.0% in the 1st quarter. MMCAP International Inc. SPC now owns 375,000 shares of the company's stock valued at $82,000 after purchasing an additional 250,000 shares in the last quarter. Finally, Context Capital Management LLC purchased a new position in Phoenix Biotech Acquisition in the 1st quarter valued at $44,000.

一些機構投資者最近增持或減持了該股。Clear Street LLC在第二季度收購了菲尼克斯生物技術公司的新股份,價值3.3萬美元。MMCAP International Inc.SPC在第一季度增持了200.0%的菲尼克斯生物科技收購股份。MmCap International Inc.SPC現在持有375,000股該公司股票,價值82,000美元,上個季度又購買了250,000股。最後,Context Capital Management LLC在第一季度收購了菲尼克斯生物技術公司的一個新頭寸,價值4.4萬美元。

About Phoenix Biotech Acquisition

關於收購菲尼克斯生物科技公司

(Get Rating)
(獲取評級)

Phoenix Biotech Acquisition Corp. intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. It focuses on pursuing opportunities in the life sciences sector. The company was incorporated in 2021 and is based in Oakland, California.

菲尼克斯生物技術收購公司打算通過合併、股份交換、股份購買、重組或類似的業務合併來收購資產和業務。它專注於在生命科學領域尋找機會。該公司成立於2021年,總部設在加利福尼亞州奧克蘭。

Read More

閲讀更多內容

  • Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAXW)
  • Why This Dip in Advanced Auto Parts May be an Opportunity
  • MarketBeat: Week in Review 8/22 – 8/26
  • Institutional Buying Put A Bottom In Marvell Technology
  • Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
  • 3 Reasons Dollar General's Rally Has Legs
  • 免費獲取StockNews.com關於鳳凰生物科技收購的研究報告(PBAXW)
  • 為什麼進軍高級汽車零部件可能是一個機會
  • MarketBeat:回顧中的一週8/22-8/26
  • 機構買入讓Marvell科技陷入低谷
  • 戴爾股票因銷售疲軟而回落,跌入可怕的價值
  • Dollar General的拉力賽有三個理由

Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.

獲得《鳳凰生物科技收購日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對菲尼克斯生物技術收購和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論